DM Clinical Research - Philadelphia

Philadelphia, Pennsylvania 19107

3 studies enrolling now · 17 studies all time

What they study most

COVID-19, COVID-19 (Coronavirus Disease 2019), Chronic Obstructive Pulmonary Disease (COPD), Clostridioides Difficile Associated Disease, Epstein-Barr Virus Infection, Healthy Adults, Herpes Zoster, Influenza, Influenza, Human, Pneumococcal Vaccines, Respiratory Syncytial Virus, Respiratory Syncytial Virus (RSV)

Studies at this site

• To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment — Recruiting now
• A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older — Recruiting now
• A Study to Learn About mRNA Vaccines Against Influenza in Adults — Recruiting now
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age — Stopped early
• A Study About Modified RNA Vaccines Against Influenza in Healthy Adults — Completed
• A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years — Completed
• Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) — Running, not enrolling
• A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People — Completed
• A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults — Completed
• A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age — Completed
• A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) — Completed
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants — Running, not enrolling
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age — Completed
• A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age — Completed
• Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults — Completed
• A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus — Completed